Integrinβ6-targeted  	Integrinβ6-targeted  	 FW	B-NP
immunoliposomes  	immunoliposomes  	 FW	I-NP
mediate  	mediate  	 FW	O
tumor-specific  	tumor-specific  	 JJ	B-NP
drug  	drug  	 NN	I-NP
delivery  	delivery  	 NN	I-NP
and  	and  	 CC	O
enhance  	enhance  	 VB	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
in  	in  	 IN	O
colon  	colon  	 FW	B-NP
carcinoma  	carcinoma  	 FW	I-NP
Adjuvant  	Adjuvant  	 FW	I-NP
chemotherapy  	chemotherapy  	 FW	I-NP
is  	is  	 VBZ	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
significant  	significant  	 JJ	O
treatments  	treatments  	 NNS	O
for  	for  	 IN	O
colon  	colon  	 NN	O
cancer  	cancer  	 NN	O
in  	in  	 IN	O
clinic 	clinic 	 NN	O
.  	.  	 .	O
However 	However 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
does  	does  	 VBZ	O
not  	not  	 RB	O
achieve  	achieve  	 VB	O
the  	the  	 DT	O
desired  	desired  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
efficacy 	efficacy 	 NN	I-NP
,  	,  	 ,	O
largely  	largely  	 RB	O
due  	due  	 JJ	O
to  	to  	 TO	O
chemotherapeutic  	chemotherapeutic  	 VB	O
resistance 	resistance 	 NN	O
.  	.  	 .	O
Integrinβ6  	Integrinβ6  	 NNP	B-NP
( 	( 	 -LRB-	O
ITGB6 	ITGB6 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
expressed  	expressed  	 VBN	O
in  	in  	 IN	O
malignant  	malignant  	 JJ	O
colonic  	colonic  	 JJ	B-NP
epithelia 	epithelia 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
not  	not  	 RB	O
in  	in  	 IN	O
normal  	normal  	 JJ	B-NP
epithelia 	epithelia 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
the  	the  	 DT	O
progression 	progression 	 NN	O
,  	,  	 ,	O
metastasis 	metastasis 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
chemotherapeutic  	chemotherapeutic  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
of  	of  	 IN	O
colon  	colon  	 NN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
Accordingly 	Accordingly 	 RB	O
,  	,  	 ,	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
necessary  	necessary  	 JJ	O
to  	to  	 TO	O
design  	design  	 VB	O
therapeutic  	therapeutic  	 JJ	B-NP
approaches  	approaches  	 NNS	I-NP
for  	for  	 IN	O
efficient  	efficient  	 JJ	O
and  	and  	 CC	O
targeted  	targeted  	 JJ	O
drug  	drug  	 NN	B-NP
delivery  	delivery  	 NN	I-NP
into  	into  	 IN	O
ITGB6-positive  	ITGB6-positive  	 CD	B-NP
cancer  	cancer  	 NN	I-NP
cells  	cells  	 NNS	I-NP
to  	to  	 TO	O
improve  	improve  	 VB	O
chemotherapeutic  	chemotherapeutic  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
in  	in  	 IN	O
colon  	colon  	 NN	O
cancer 	cancer 	 NN	O
.  	.  	 .	O
PEGylated  	PEGylated  	 JJ	B-NP
liposomes  	liposomes  	 NN	I-NP
were  	were  	 VBD	O
employed  	employed  	 VBN	O
to  	to  	 TO	O
design  	design  	 VB	O
ITGB6-targeted  	ITGB6-targeted  	 CD	B-NP
immunoliposomes 	immunoliposomes 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
have  	have  	 VBP	O
ITGB6  	ITGB6  	 RB	O
monoclonal  	monoclonal  	 JJ	B-NP
antibodies  	antibodies  	 NNS	I-NP
( 	( 	 -LRB-	O
mAbs 	mAbs 	 NNP	B-NP
)  	)  	 -RRB-	O
conjugated 	conjugated 	 NN	O
.  	.  	 .	O
We  	We  	 PRP	O
evaluated  	evaluated  	 VBD	O
the  	the  	 DT	O
ITGB6-targeted  	ITGB6-targeted  	 JJ	B-NP
immunoliposomes  	immunoliposomes  	 JJ	I-NP
internalization  	internalization  	 NN	I-NP
into  	into  	 IN	O
colon  	colon  	 NN	O
cancer  	cancer  	 NN	O
cells  	cells  	 NNS	O
and  	and  	 CC	O
examined  	examined  	 JJ	O
5-fluorouracil  	5-fluorouracil  	 NN	B-NP
( 	( 	 -LRB-	O
5-FU 	5-FU 	 NNP	B-NP
) 	) 	 -RRB-	O
-induced  	-induced  	 JJ	O
cellular  	cellular  	 JJ	O
apoptosis  	apoptosis  	 NNS	O
produced  	produced  	 VBN	O
by  	by  	 IN	O
ITGB6-targeted  	ITGB6-targeted  	 CD	B-NP
immunoliposomes+5-FU 	immunoliposomes+5-FU 	 CD	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
biodistribution  	biodistribution  	 NN	B-NP
and  	and  	 CC	O
antitumor  	antitumor  	 JJ	B-NP
efficiency  	efficiency  	 NN	I-NP
of  	of  	 IN	I-NP
ITGB6-targeted  	ITGB6-targeted  	 CD	I-NP
immunoliposomes  	immunoliposomes  	 NNS	I-NP
were  	were  	 VBD	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
vivo 	vivo 	 NN	B-NP
.  	.  	 .	O
ITGB6-targeted  	ITGB6-targeted  	 NNP	B-NP
immunoliposomes  	immunoliposomes  	 VBD	O
enhanced  	enhanced  	 VBN	O
cellular  	cellular  	 JJ	B-NP
internalization  	internalization  	 NN	I-NP
in  	in  	 IN	O
ITGB6-positive  	ITGB6-positive  	 CD	B-NP
colon  	colon  	 NN	I-NP
cancer  	cancer  	 NN	I-NP
cells  	cells  	 NNS	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
liposomes 	liposomes 	 NN	B-NP
.  	.  	 .	O
Furthermore 	Furthermore 	 RB	O
,  	,  	 ,	O
the  	the  	 DT	O
ITGB6-targeted  	ITGB6-targeted  	 CD	B-NP
immunoliposome  	immunoliposome  	 CD	I-NP
internalization  	internalization  	 NNS	I-NP
was  	was  	 VBD	O
dependent  	dependent  	 JJ	O
on  	on  	 IN	O
the  	the  	 DT	O
ITGB6  	ITGB6  	 JJ	B-NP
expression  	expression  	 NN	I-NP
level  	level  	 NN	I-NP
on  	on  	 IN	O
cellular  	cellular  	 JJ	B-NP
surface 	surface 	 NN	I-NP
.  	.  	 .	O
ITGB6-targeted  	ITGB6-targeted  	 NNP	B-NP
immunoliposomes  	immunoliposomes  	 NN	I-NP
decreased  	decreased  	 VBD	O
the  	the  	 DT	O
5-FU  	5-FU  	 CD	O
IC50  	IC50  	 CD	O
more  	more  	 JJR	O
than  	than  	 IN	O
90 	90 	 CD	O
%  	%  	 NN	O
in  	in  	 IN	O
HT-29  	HT-29  	 NNP	B-NP
and  	and  	 CC	O
SW480β6  	SW480β6  	 CD	B-NP
cells  	cells  	 NNS	I-NP
relative  	relative  	 JJ	O
to  	to  	 TO	O
liposomes 	liposomes 	 VB	O
.  	.  	 .	O
Moreover 	Moreover 	 RB	O
,  	,  	 ,	O
when  	when  	 WRB	O
loaded  	loaded  	 VBN	O
with  	with  	 IN	O
5-FU 	5-FU 	 NNP	O
,  	,  	 ,	O
ITGB6-targeted  	ITGB6-targeted  	 CD	B-NP
immunoliposomes  	immunoliposomes  	 NNS	I-NP
produced  	produced  	 VBD	O
an  	an  	 DT	O
approximately  	approximately  	 RB	O
1.5-fold  	1.5-fold  	 CD	O
higher  	higher  	 JJR	O
5-FU-induced  	5-FU-induced  	 JJ	O
cellular  	cellular  	 JJ	O
apoptosis  	apoptosis  	 JJ	O
rate  	rate  	 NN	O
than  	than  	 IN	O
liposomes 	liposomes 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
vivo 	vivo 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
therapeutic  	therapeutic  	 JJ	B-NP
activity  	activity  	 NN	I-NP
of  	of  	 IN	I-NP
ITGB6-targeted  	ITGB6-targeted  	 NNP	I-NP
immunoliposomes+5-FU  	immunoliposomes+5-FU  	 NNP	I-NP
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
superior 	superior 	 JJ	O
,  	,  	 ,	O
resulting  	resulting  	 VBG	O
in  	in  	 IN	O
25 	25 	 CD	O
%  	%  	 NN	O
to  	to  	 TO	O
35 	35 	 CD	O
%  	%  	 NN	O
reduction  	reduction  	 NN	O
of  	of  	 IN	O
tumor  	tumor  	 NN	B-NP
weight  	weight  	 NN	I-NP
compared  	compared  	 VBN	O
with  	with  	 IN	O
5-FU  	5-FU  	 NNP	O
or  	or  	 CC	O
liposomes+5-FU 	liposomes+5-FU 	 NNP	B-NP
.  	.  	 .	O
ITGB6-targeted  	ITGB6-targeted  	 NNP	B-NP
immunoliposomes  	immunoliposomes  	 NNS	I-NP
provide  	provide  	 VBP	O
a  	a  	 DT	O
highly  	highly  	 RB	O
efficient  	efficient  	 JJ	O
approach  	approach  	 NN	O
for  	for  	 IN	O
targeted  	targeted  	 JJ	O
drug  	drug  	 NN	B-NP
delivery  	delivery  	 NN	I-NP
in  	in  	 IN	O
colon  	colon  	 NN	O
cancer  	cancer  	 NN	O
and  	and  	 CC	O
thus  	thus  	 RB	O
offer  	offer  	 VB	O
the  	the  	 DT	O
potential  	potential  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
novel  	novel  	 NN	O
and  	and  	 CC	O
promising  	promising  	 JJ	O
anticancer  	anticancer  	 JJ	B-NP
strategy  	strategy  	 NN	I-NP
for  	for  	 IN	I-NP
clinical  	clinical  	 JJ	I-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
